Potential for imaging the high-affinity state of the 5-HT1B receptor: a comparison of three PET radioligands with differing intrinsic activity

被引:5
|
作者
Lindberg, Anton [1 ,2 ,3 ]
Arakawa, Ryosuke [1 ,2 ]
Nogami, Tsuyoshi [1 ,2 ]
Nag, Sangram [1 ,2 ]
Schou, Magnus [1 ,2 ,5 ]
Elmore, Charles S. [4 ]
Farde, Lars [1 ,2 ,5 ]
Pike, Victor W. [3 ]
Halldin, Christer [1 ,2 ]
机构
[1] Karolinska Inst, Ctr Psychiat Res, Dept Clin Neurosci, SE-17176 Stockholm, Sweden
[2] Stockholm Cty Council, SE-17176 Stockholm, Sweden
[3] NIMH, Mol Imaging Branch, NIH, Bethesda, MD 20892 USA
[4] AstraZeneca, Pharmaceut Sci R&D, Early Chem Dev, Isotope Chem, SE-43250 Gothenburg, Sweden
[5] AstraZeneca, R&D, Precis Med & Genom, PET Sci Ctr, SE-17176 Stockholm, Sweden
基金
美国国家卫生研究院;
关键词
5-HT1B; PET; Radioligand; Agonist; Antagonist; SEROTONIN RELEASE; BRAIN; BINDING; TARGET;
D O I
10.1186/s13550-019-0570-1
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Background Over the last decade, a few radioligands have been developed for PET imaging of brain 5-HT1B receptors. The 5-HT1B receptor is a G-protein-coupled receptor (GPCR) that exists in two different agonist affinity states. An agonist ligand is expected to be more sensitive towards competition from another agonist, such as endogenous 5-HT, than an antagonist ligand. It is of interest to know whether the intrinsic activity of a PET radioligand for the 5-HT1B receptor impacts on its ability to detect changes in endogenous synaptic 5-HT density. Three high-affinity C-11-labeled 5-HT1B PET radioligands with differing intrinsic activity were applied to PET measurements in cynomolgus monkey to evaluate their sensitivity to be displaced within the brain by endogenous 5-HT. For these experiments, fenfluramine was pre-administered at two different doses (1.0 and 5.0 mg/kg, i.v.) to induce synaptic 5-HT release. Results A dose-dependent response to fenfluramine was detected for all three radioligands. At the highest dose of fenfluramine (5.0 mg/kg, i.v.), reductions in specific binding in the occipital cortex increased with radioligand agonist efficacy, reaching 61% for [C-11]3. The most antagonistic radioligand showed the lowest reduction in specific binding. Conclusions Three 5-HT1B PET radioligands were identified with differing intrinsic activity that could be used in imaging high- and low-affinity states of 5-HT1B receptors using PET. From this limited study, radioligand sensitivity to endogenous 5-HT appears to depend on agonist efficacy. More extensive studies are required to substantiate this suggestion.
引用
收藏
页数:8
相关论文
共 50 条
  • [41] PREFERENCE OF RU-24969 AND PINDOLOL FOR THE PURPORTED 5-HT1B BINDING-SITE - CORRELATION BETWEEN 5-HT1A AFFINITY AND HYPOTENSIVE ACTIVITY
    DOODS, HN
    KALKMAN, HO
    DEJONGE, A
    WILFFERT, B
    THOOLEN, MJMC
    TIMMERMANS, PBMWM
    VANZWIETEN, PA
    PHARMACEUTISCH WEEKBLAD-SCIENTIFIC EDITION, 1984, 6 (04) : 168 - 168
  • [42] F 11356, a novel 5-hydroxytryptamine (5-HT) derivative with potent, selective, and unique high intrinsic activity at 5-HT1B/1D receptors in models relevant to migraine
    John, GW
    Pauwels, PJ
    Perez, M
    Halazy, S
    Le Grand, B
    Verscheure, Y
    Valentin, JP
    Palmier, C
    Wurch, T
    Chopin, P
    Marien, M
    Kleven, MS
    Koek, W
    Assie, MB
    Carilla-Durand, E
    Tarayre, JP
    Colpaert, FC
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 1999, 290 (01): : 83 - 95
  • [43] Development of a PET radioligand for the central 5-HT1B receptor: radiosynthesis and characterization in cynomolgus monkeys of eight radiolabeled compounds
    Andersson, Jan D.
    Pierson, M. Edward
    Finnema, Sjoerd J.
    Gulyas, Balazs
    Heys, Richard
    Elmore, Charles S.
    Farde, Lars
    Halldin, Christer
    NUCLEAR MEDICINE AND BIOLOGY, 2011, 38 (02) : 261 - 272
  • [44] N-4-UNSUBSTITUTED N-1-ARYLPIPERAZINES AS HIGH-AFFINITY 5-HT1A RECEPTOR LIGANDS
    KUIPERS, W
    VANWIJNGAARDEN, I
    KRUSE, CG
    TERHORSTVANAMSTEL, M
    TULP, MTM
    IJZERMAN, AP
    JOURNAL OF MEDICINAL CHEMISTRY, 1995, 38 (11) : 1942 - 1954
  • [45] SYNTHESIS AND IN VITRO AFFINITIES OF VARIOUS MDL 100907 DERIVATIVES AS POTENTIAL 18F-RADIOLIGANDS FOR 5-HT2A RECEPTOR IMAGING WITH PET
    Herth, M.
    Kramer, V.
    Piel, M.
    Palner, M.
    Riss, P.
    Knudsen, G.
    Roesch, F.
    JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS, 2009, 52 : S391 - S391
  • [46] 5-thienyltryptamine derivatives as serotonin 5-HT1B/1D receptor agonists: Potential treatment for migraine.
    Slassi, AM
    Meng, CQ
    Rakhit, S
    Wang, X
    Lee, DKH
    Dyne, K
    McCallum, KL
    Mazzacco, L
    Kamboj, R
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2000, 219 : U58 - U58
  • [47] Synthesis and in vitro affinities of various MDL 100907 derivatives as potential 18F-radioligands for 5-HT2A receptor imaging with PET
    Herth, Matthias M.
    Kramer, Vasko
    Piel, Markus
    Palner, Mikael
    Riss, Patrick J.
    Knudsen, Gitte M.
    Roesch, Frank
    BIOORGANIC & MEDICINAL CHEMISTRY, 2009, 17 (08) : 2989 - 3002
  • [48] 1-(M-CHLOROPHENYL)-BIGUANIDE, A POTENT HIGH-AFFINITY 5-HT3 RECEPTOR AGONIST
    KILPATRICK, GJ
    BUTLER, A
    BURRIDGE, J
    OXFORD, AW
    EUROPEAN JOURNAL OF PHARMACOLOGY, 1990, 182 (01) : 193 - 197
  • [49] Selective 5-HT1B receptor inhibition of glutamatergic and GABAergic synaptic activity in the rat dorsal and median raphe
    Lemos, Julia C.
    Pan, Yu-Zhen
    Ma, Xiaohong
    Lamy, Christophe
    Akanwa, Adaure C.
    Beck, Sheryl G.
    EUROPEAN JOURNAL OF NEUROSCIENCE, 2006, 24 (12) : 3415 - 3430
  • [50] RS-127445: A selective, high-affinity, orally bioavailable 5-HT2B receptor antagonist.
    Flippin, LA
    Bonhaus, DW
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 1999, 218 : U971 - U971